RxDoctor Payments Data

Dennis Woodling, MD

Internal Medicine · Montgomery, ALNPI 1972697464

Payments from drug & device makers

$13,026in general payments, 2019–2025

Across 801 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Pfizer$948
  • Novo Nordisk$944
  • Lilly USA, LLC$868
  • AstraZeneca$819
  • plus $7K from 50 others

What the payments were for

  • Food & beverage$12,94199%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,026 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$125,516
Medicare patients
309
Services billed
2,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide151$157,845
MyrbetriqMirabegron175$117,507
JardianceEmpagliflozin120$104,217
EliquisApixaban96$100,384
OzempicSemaglutide71$69,441
FarxigaDapagliflozin Propanediol79$63,623
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$46,394
VraylarCariprazine Hcl25$43,754
JanumetSitagliptin Phos/Metformin Hcl53$41,784
LinzessLinaclotide71$38,040
RybelsusSemaglutide24$27,848
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$27,542
TrulicityDulaglutide26$26,018
Janumet XrSitagliptin Phos/Metformin Hcl37$25,430
GemtesaVibegron27$21,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$868$183,862177 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Jentadueto$368$119,433145 claims
Astellas Pharma US IncMyrbetriq$680$117,507175 claims
PfizerEliquis, Premarin$948$108,466117 claims
Novo NordiskOzempic, Rybelsus$944$97,28995 claims
MerckJanumet, Janumet Xr, Januvia$472$83,018110 claims
AbbVieVraylar, Linzess$1,458$81,79596 claims
GSKTrelegy Ellipta, Anoro Ellipta$626$64,581101 claims
AstraZenecaFarxiga$819$63,62379 claims
Sumitomo Pharma America, Inc.Gemtesa$429$21,85027 claims
Johnson & JohnsonInvokana, Xarelto$168$19,65334 claims
Kowa Pharmaceuticals America, Inc.Livalo$23$12,22617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →